First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Yuankai Shi, Sheng Hou, Junye Wang et al.|Signal Transduction and Targeted Therapy|2025

Cited by 8